Drug Profile
Research programme: bispecific antibody-drug conjugates - Genmab/Unknown
Alternative Names: bispecific antibody-drug conjugate; DuoBody-ADCLatest Information Update: 01 Mar 2023
Price :
$50
*
At a glance
- Originator Genmab
- Class Antineoplastics; Bispecific antibodies; Drug conjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 01 Mar 2023 Preclinical development in Solid-tumours is ongoing in Denmark (Genmab pipeline; February 2023)
- 28 Feb 2023 No recent reports of development identified for preclinical development in Solid-tumours in Denmark (Parenteral)
- 28 Mar 2018 No recent reports of development identified for preclinical development in Solid-tumours in Denmark (Parenteral)